IBA takes 25% stake in German  radiopharmaceuticals supplier PET Net

19 April 2011

Belgian company Ion Beam Applications (IBA) S.A. has taken a minority stake in PET Net GmbH and PET Net Solutions AG, providers of PET radiopharmaceuticals to nuclear medicine facilities in Germany.

Under the terms of the agreement, IBA has purchased 25.2% of PET Net from its owner, Medical Imaging Research Holding GmbH.

IBA says the acquisition reinforces its position as the leading global supplier of PET radiopharmaceuticals and provides a local partner in Germany for developing and distributing future proprietary molecules.

PET Net operates two profitable commercial GMP-certified PET sites located in Erlangen and Regensburg, Germany, has a European marketing authorization for FDG, a PET radiopharmaceutical used in oncology, and is a service provider for establishing PET production sites.

IBA, which already has a German subsidiary, CIS bio GmbH, providing SPECT products, will now have access to a local PET infrastructure to build the foundation for a PET offering and round out its nuclear medicine portfolio in Germany, a key radiopharmaceuticals market.

“IBA’s growth strategy has focused on expanding its manufacturing and distribution network in every major nuclear medicine market, and having a PET infrastructure in Germany was a critical element of this development,” said Pierre Mottet, chief executive officer of IBA. “IBA’s acquisition of shares in PET Net supports the uniqueness of our global network and brings the company one step closer to consolidating its position as market leader in next generation radiopharmaceuticals used in personalized medicine on a global scale.”

“PET Net and IBA share a joint mission, that of improving patient care,” said Professor Willi Kalender, founder and owner of PET Net. “I chose the name PET Net when founding the company in 1998 to make it clear from the start that a network is the goal. By partnering and joining complementing areas of expertise, we can facilitate this mission and develop novel proprietary molecules for the German radiopharmaceuticals market.”

PET is a non-invasive method used in molecular imaging to visualize biological processes for the early detection and real-time monitoring of diseases. By providing doctors with information about a body’s function as well as structure, diseases and their response to treatment can be imaged at a very early stage, which can lead to earlier, safer and more effective treatments.

As PET radiopharmaceuticals must be delivered within a crucial window of time, IBA’s unique network of facilities enables it to quickly supply safe and reliable solutions to nuclear medicine specialists across the globe.


To top